
Soriano Lab
@sorianolab
Research group at @UniPadova focused on the study of mitochondrial biology and metabolism. Mageni's tweets are signed MS.
ID: 1481595504287006724
https://www.labsoriano.com/ 13-01-2022 11:56:37
18 Tweet
245 Followers
236 Following


Happy to share our recent work on mitochondrial translation termination by franzinadler et al.: biorxiv.org/content/10.110… We solved a long-standing mystery and explain the function and specificity of canonical and non-canonical mitochondrial release factors (mtRF1a vs mtRF1).


Latest Biomed News in #Cancer #Bioenergetics - biomed.news/bims-mibica/20…. Lab pick from eLife - the journal demonstrating that mtDNA deletions are genetically regulated as a defense against short-term ROS damage (in yeast). Very cool! elifesciences.org/articles/76095



Fantastic paradigm shift in understanding mtDNA gene expesision! Mito@GU, Minczuk Lab, @NCL_mtDNA.So happy that the first author Ben Tan Benedict Tan wiil join my group in 10 days! cell.com/molecular-cell…




We are very happy and proud that Luca was recognised with the very first Margaret Lewis award for the recognition of excellence in the mitochondria biology field Gordon Research Conferences


A Two Year Post-doctoral Position is available in the Soriano Lab, Department of Biology – University of Padova, Università di Padova. This is a unique opportunity 👇Stellar Lab and Stellar PI. APPLY!!!!!!


PostDoc position available to TMEM65 protein and related disorders in Soriano Lab ! 🇮🇹🍕With great collaborators Milena Bellin Telethon-Cariplo Grant. Fondazione Cariplo @Telethonitalia Department of Biology – University of Padova


Excited to share one more 2023 research story from our lab, out today Cancer Discovery identifying #Mitochondria and #Mitophagy as a key regulator of Venetoclax and MCL1i resistance in AML. The work was led by Christina Glytsou and xufeng chen ...NYU Grossman School of Medicine (1) aacrjournals.org/cancerdiscover…

Mito dynamics seems crucial for cancer resistance to therapy. Check our recent papers from masafumi noguchi on how our Opa1 inhibitor MYLS22 reverts gefitinib resistance in NSCLC rdcu.be/daF7C and from MargheritaZamberlan on how MYLS22 treats TNBC models rdcu.be/daF8z! 2/3
